How does a bearing production enterprise realize its magnificent turn to a pharmaceutical enterprise?​​

​​

After completing the second transformation of its own reform, how does it continue to maintain a successful lead?​​

​​

Founded in 2008, Wanbangde Group is a high-tech private enterprise mainly engaged in the research, development, production and operation of pharmaceutical raw materials and its preparation products. It owns three pillar industries of pharmaceuticals, bearings and medical care. , China Famous Brand Enterprise and Top Ten Industrial Enterprises in Wenling City.

​​

Since 2009, it has been increasing at a rate of 50% every year, with annual sales from 200 million yuan in 2012 to 350 million yuan in 2013, and this year is expected to exceed 1 billion yuan. What kind of conceptual support has it maintained such a steady development momentum?​​

​​

The transformation journey of a ginkgo leaf

​​

Zhejiang Wanbang Pharmaceutical Co., Ltd. is located in the Economic Development Zone of Wenling City. Walking into its clean and tidy aseptic workshop, the reporter saw that in the closed space of the assembly line, black grains of rice grain size made from ginkgo biloba leaves The small balls are packed into thin strips under the flow of the automatic production line, and then packed into boxes and boxes.​​

​​

These are four new automatic packaging lines for ginkgo biloba drop pills newly installed by Wanbang Pharmaceutical this year, each of which requires an investment of 12 million yuan. "One production line only needs 4 people, and 6 production lines can reduce 300 employees. After all 6 production lines are installed, the annual production capacity will reach 6 billion capsules." Zhao Shouming, chairman and general manager of Wanbang Pharmaceutical, told reporters.​​

​​

Ginkgo biloba dripping pills are the star product of Wanbang Pharmaceutical. The dosage form of drop pills is not metabolized by the liver, it is directly absorbed through the capillaries, and the medication is relatively safe. As an upgraded product of modern new oral preparations of traditional Chinese medicine and a first-line drug for the prevention and treatment of cardiovascular and cerebrovascular diseases, Ginkgo biloba dripping pills are increasingly favored by the market. It has successively entered the national protected varieties of traditional Chinese medicines, the national exclusive production varieties, and the national essential medicines list. At present, there is no such dosage form of Ginkgo biloba in foreign countries.​​

​​

However, what surprised people was that Wanbang's first transformation was from machinery to pharmaceutical industry.​​

​​

The predecessor of this large-scale quasi-listed company is Wanbang Bearing Company founded in 1990, specializing in the production of bearing products, which have been exported to more than 30 countries and regions. In August 2002, Wanbang adjusted its industrial structure, decisively acquired the old state-owned enterprise Wenling Pharmaceutical Factory, and established Zhejiang Wanbang Pharmaceutical Co., Ltd.

A small ginkgo leaf laid the cornerstone of the development of Wanbang Pharmaceutical. And it has gone through nearly 20 years from research and development to production, to development and growth.​​

Before getting the approval number of Ginkgo Leaf Dropping Pills, a well-known pharmaceutical company in the north wanted to buy the right to transfer new drugs at a price of 20 million yuan. 20 million yuan, which is a large amount for Wanbang, which has just started, but Zhao Shouming thought about it again and again and finally rejected the deal. Because of the "war of attrition" in bearing anti-dumping, he deeply realized that in order to survive and grow, an enterprise must have long-term development goals, must have market competitiveness, high-tech main products, and must have their own core intellectual property rights.​​

At present, Wanbang Pharmaceutical has 8 subsidiaries including Wenling Tongda Fine Chemicals Co., Ltd., Hunan Lushan Natural Plant Pharmaceutical Co., Ltd., Zhejiang Zhengyi Pharmaceutical Co., Ltd., and Jiangsu Besikang Pharmaceutical Co., Ltd. There are 198 drug production approval numbers, 60 varieties and 76 product specifications have entered the 2012 version of the National Essential Drugs List, and 69 varieties have entered the national cheap drugs. Among them, the sales volume of ginkgo leaf dropping pills was 16 million bottles in 2013, 30 million bottles in 2014, and 50 million bottles in 2015.​​

The second transformation, what does Wanbang rely on to successfully lead?

The launch of the new product Huperzine A started the engine for the second take-off of Wanbang Pharmaceutical. Huperzine A, which is "nationally original and international first", has won the gold medal of the 3rd National Invention Exhibition, the gold medal of the French Eureka International Expo and the second prize of the National Invention Award, and has been included in the national key innovation project.​​

It ranks with donepezil and memantine as the three giants in the global treatment of Alzheimer's disease. And only Huperzine A has full intellectual property rights in China and is a product extracted from pure traditional Chinese medicine.​​

Wanbang Pharmaceutical is the first company in China to obtain the registration approval of Huperzine A API. "Huperzine A has broken through key technical barriers, converting from the original pure Chinese medicine extraction to chemical synthesis, which greatly reduces the cost, and has applied for international and domestic invention patents for the synthesis of Huperzine A." Zhao Shouming proudly Tell the reporter, "Next, we will make a series of products of Huperzine A."

Wanbang also plans to cultivate 10 products with a single variety of over 100 million yuan on the basis of its own 198 products in terms of national low-cost drugs and essential drugs, and these are all for the further development of Wanbang. Plug in the wings of soaring.​​

In addition to the continuous R&D and launch of new products, the change in sales model also brings impetus to the development and growth of Wanbang. In September 2013, the sales headquarters of Wanbang Pharmaceutical returned to Wenling, and this sales team has nearly 2,000 people across the country. "Wenling Municipal Party Committee and Municipal Government also supported us and issued corresponding support policies. As an enterprise, we are full of confidence in the future development." Zhao Shouming said.​​

The day after the interview, he will go to the United States, "I will be there for a month in July to do pre-research work on the internationalization of preparations. We have obtained the patent for Huperzine A, and we have started pre-clinical preparations to prepare for the U.S. FDA declaration, let Wanbang's preparation products embark on the road of internationalization."

Leading transformation and upgrading with technological innovation

This year, Wanbang invested 40 million yuan for new product research and development and technology improvement. On the basis of consolidating the original resource advantages, more emphasis is placed on scientific and technological innovation. The development of new drugs and special drugs that meet market demands and have higher technical content has become the only way for Wanbang Pharmaceutical to grow.​​

The company introduced a number of senior engineers with rich practical experience as technical backbones, and established Wanbang Pharmaceutical Cardiovascular and Cerebrovascular Drug Research and Development Center. At present, the center has more than 200 sets of imported advanced equipment such as the world's most advanced Chinese medicine extraction, separation and refined series of pharmaceutical equipment and American Waters high-performance liquid chromatography, gas chromatography, polarimeter, etc. There are 138 scientific and technological personnel with college degree or above, and 79 R&D personnel.​​

In 2012, Wanbang Pharmaceutical R&D Center established a long-term cooperative relationship of production, learning and research with Zhejiang University of Technology, engaged in the research and development of new products and technical innovation consulting of original products. A number of units carry out technical cooperation.​​

At present, the new drug varieties independently developed by the company include Ginkgo biloba dropping pills, risperidone dispersible tablets, Huperzine A series products, plastic Anbo injection products, inhalation solution products, Melaleuca controlled-release tablets and dropping pills and other new drugs product. The efficacy of the products covers cardiovascular and cerebrovascular, nervous system, respiratory system, digestive system, immune system, gynecological system and other disease treatment fields.​​

Last year, Wanbang achieved a total sales of 350 million yuan, handed over 57 million yuan in profits and taxes, and realized a profit of 67 million yuan. From January to May this year, Wanbang's sales exceeded 220 million yuan, and the tax paid reached 47 million yuan.